← Leaderboards
James W Mier
Brigham And Women'S Hospital
$3,282,868
Attributed
$3,282,868
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $474.4K · FY2005–19$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,282,868 · 8
By mechanism
P50$2,919,126 · 5
R21$306,000 · 1
M01$57,742 · 2
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Joseph Loscalzo$36,255,197
- Hiroko Yano$3,533,714
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsPharmaceutical PreparationsTumorInhibitor/AntagonistDrug DevelopmentCellsSignal TransductionResponseNeoplastic CellBaseEventProteinsBay 54-9085MelanomaIn VivoCell GrowthMitogen-Activated Protein KinasesPathway InteractionsApoptosisMolecularAngiogenesisGrantCell LineCell Survival
Grant awards (19)
Small Molecule HIF2a Inhibitors for Treatment of Renal Cell Carcinoma$270,183
P50 · FY2019 · CA · contact PI
HDM2 as a Therapeutic Target in RCC$236,861
P50 · FY2018 · CA · contact PI
HDM2 as a Therapeutic Target in RCC$237,240
P50 · FY2017 · CA · contact PI
P4 - Treating the P13-Kinase/AKT$140,848
P50 · FY2013 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$259,801
P50 · FY2012 · CA · contact PI
P4 - Treating the P13-Kinase/AKT$147,424
P50 · FY2012 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$294,646
P50 · FY2011 · CA · contact PI
P4 - Treating the P13-Kinase/AKT$139,982
P50 · FY2011 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$326,994
P50 · FY2010 · CA · contact PI
P4 - Treating the P13-Kinase/AKT$147,443
P50 · FY2010 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$320,636
P50 · FY2009 · CA · contact PI
Treating the P13-Kinase/AKT$147,910
P50 · FY2009 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$249,158
P50 · FY2008 · CA · contact PI
PHASE I CLINICAL TRIAL OF DECITABINE PRIOR TO DACARBAZINE IN ADVANCED MELANOMA$9,049
M01 · FY2006 · RR · contact PI
PHASE I CLINICAL TRIAL OF DECITABINE PRIOR TO DACARBAZINE IN ADVANCED MELANOMA$48,693
M01 · FY2005 · RR
Clinical Trials with IL12$153,000
R21 · FY2002 · CA
CORE--IMMUNE MONITORING$0
P50 · FY2002 · CA
Clinical Trials with IL12$153,000
R21 · FY2001 · CA
CORE--IMMUNE MONITORING$0
P50 · FY2001 · CA